Literature DB >> 33807854

Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.

Chunguang Liang1, Elena Bencurova1, Eric Psota2, Priya Neurgaonkar1, Martina Prelog2, Carsten Scheller3, Thomas Dandekar1.   

Abstract

We observed substantial differences in predicted Major Histocompatibility Complex II (MHCII) epitope presentation of SARS-CoV-2 proteins for different populations but only minor differences in predicted MHCI epitope presentation. A comparison of this predicted epitope MHC-coverage revealed for the early phase of infection spread (till day 15 after reaching 128 observed infection cases) highly significant negative correlations with the case fatality rate. Specifically, this was observed in different populations for MHC class II presentation of the viral spike protein (p-value: 0.0733 for linear regression), the envelope protein (p-value: 0.023), and the membrane protein (p-value: 0.00053), indicating that the high case fatality rates of COVID-19 observed in some countries seem to be related with poor MHC class II presentation and hence weak adaptive immune response against these viral envelope proteins. Our results highlight the general importance of the SARS-CoV-2 structural proteins in immunological control in early infection spread looking at a global census in various countries and taking case fatality rate into account. Other factors such as health system and control measures become more important after the early spread. Our study should encourage further studies on MHCII alleles as potential risk factors in COVID-19 including assessment of local populations and specific allele distributions.

Entities:  

Keywords:  B-cell; COVID-19; MHC I; MHC II; SARS-CoV-2; T-cell; epitope mapping; infection spread; lethality rate; population coverage

Mesh:

Substances:

Year:  2021        PMID: 33807854      PMCID: PMC7961590          DOI: 10.3390/ijms22052630

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  38 in total

1.  TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates.

Authors:  Sinu Paul; John Sidney; Alessandro Sette; Bjoern Peters
Journal:  Curr Protoc Immunol       Date:  2016-08-01

2.  Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.

Authors:  Hong Zhang; Guangwen Wang; Jian Li; Yuchun Nie; Xuanling Shi; Gewei Lian; Wei Wang; Xiaolei Yin; Yang Zhao; Xiuxia Qu; Mingxiao Ding; Hongkui Deng
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines.

Authors:  Irini A Doytchinova; Darren R Flower
Journal:  BMC Bioinformatics       Date:  2007-01-05       Impact factor: 3.169

4.  Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses.

Authors:  Venkata R Duvvuri; Bhargavi Duvvuri; Christilda Alice; Gillian E Wu; Jonathan B Gubbay; Jianhong Wu
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

5.  Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.

Authors:  Zahra Noorimotlagh; Chiman Karami; Seyyed Abbas Mirzaee; Mohammadreza Kaffashian; Sanaz Mami; Mahdieh Azizi
Journal:  Int Immunopharmacol       Date:  2020-06-28       Impact factor: 4.932

6.  Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein.

Authors:  Andrew D Davidson; Maia Kavanagh Williamson; Sebastian Lewis; Deborah Shoemark; Miles W Carroll; Kate J Heesom; Maria Zambon; Joanna Ellis; Philip A Lewis; Julian A Hiscox; David A Matthews
Journal:  Genome Med       Date:  2020-07-28       Impact factor: 11.117

7.  Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis.

Authors:  Shirley Sze; Daniel Pan; Clareece R Nevill; Laura J Gray; Christopher A Martin; Joshua Nazareth; Jatinder S Minhas; Pip Divall; Kamlesh Khunti; Keith R Abrams; Laura B Nellums; Manish Pareek
Journal:  EClinicalMedicine       Date:  2020-11-12

Review 8.  T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response.

Authors:  Leonard Moise; Bethany M Biron; Christine M Boyle; Nese Kurt Yilmaz; Hyesun Jang; Celia Schiffer; Ted M Ross; William D Martin; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

9.  National Disparities in COVID-19 Outcomes between Black and White Americans.

Authors:  Michael Poulson; Alaina Geary; Chandler Annesi; Lisa Allee; Kelly Kenzik; Sabrina Sanchez; Jennifer Tseng; Tracey Dechert
Journal:  J Natl Med Assoc       Date:  2020-08-07       Impact factor: 1.798

10.  A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants.

Authors:  Bethany Dearlove; Eric Lewitus; Hongjun Bai; Yifan Li; Daniel B Reeves; M Gordon Joyce; Paul T Scott; Mihret F Amare; Sandhya Vasan; Nelson L Michael; Kayvon Modjarrad; Morgane Rolland
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-31       Impact factor: 12.779

View more
  1 in total

1.  Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2.

Authors:  Joshua M Francis; Del Leistritz-Edwards; Augustine Dunn; Christina Tarr; Jesse Lehman; Conor Dempsey; Andrew Hamel; Violeta Rayon; Gang Liu; Yuntong Wang; Marcos Wille; Melissa Durkin; Kane Hadley; Aswathy Sheena; Benjamin Roscoe; Mark Ng; Graham Rockwell; Margaret Manto; Elizabeth Gienger; Joshua Nickerson; Amir Moarefi; Michael Noble; Thomas Malia; Philip D Bardwell; William Gordon; Joanna Swain; Mojca Skoberne; Karsten Sauer; Tim Harris; Ananda W Goldrath; Alex K Shalek; Anthony J Coyle; Christophe Benoist; Daniel C Pregibon
Journal:  Sci Immunol       Date:  2022-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.